MedTrace Logo

A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer

NCT04461600 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2024-02-12

Study results available
· View outcomes & findings →

Summary

The current study is designed to evaluate the efficacy and safety of AL101 monotherapy in subjects with Notch-activated recurrent or metastatic TNBC; Notch activation will be determined by a Next Generation Sequencing (NGS) test.

Conditions

Interventions

DRUG

AL101

AL101 is an inhibitor of gamma secretase-mediated Notch signaling.

Sponsors & Collaborators

  • Ayala Pharmaceuticals, Inc,

    lead INDUSTRY

Principal Investigators

  • Andres Gutierrez, MD, PhD · Executive Vice President & Chief Medical Officer

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-14
Primary Completion
2022-03-23
Completion
2022-10-11
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Israel
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04461600 on ClinicalTrials.gov